ZUG, Switzerland--(BUSINESS WIRE)--Amgen (Europe) GmbH today announced that the European Commission (EC) has approved the extension of the marketing authorization for Mimpara® (cinacalcet) in the European Union (EU) for the reduction of hypercalcemia in patients with primary hyperparathyroidism (PHPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
